Mayer, Bruce J. and Jackson, Peter K. and Van Etten, Richard A. and Baltimore, David (1992) Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Molecular and Cellular Biology, 12 (2). pp. 609-618. ISSN 0270-7306. PMCID PMC364250. http://resolver.caltech.edu/CaltechAUTHORS:MAYmcb92
- Published Version
See Usage Policy.
Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:MAYmcb92
We have constructed a series of point mutations in the highly conserved FLVRES motif of the src homology 2 (SH2) domain of the abl tyrosine kinase. Mutant SH2 domains were expressed in bacteria, and their ability to bind to tyrosine-phosphorylated proteins was examined in vitro. Three mutants were greatly reduced in their ability to bind both phosphotyrosine itself and tyrosine-phosphorylated cellular proteins. All of the mutants that retained activity bound to the same set of tyrosine-phosphorylated proteins as did the wild type, suggesting that binding specificity was unaffected. These results implicate the FLVRES motif in direct binding to phosphotyrosine. When the mutant SH2 domains were inserted into an activated abl kinase and expressed in murine fibroblasts, decreased in vitro phosphotyrosine binding correlated with decreased transforming ability. This finding implies that SH2-phosphotyrosine interactions are involved in transmission of positive growth signals by the nonreceptor tyrosine kinases, most likely via the assembly of multiprotein complexes with other tyrosine-phosphorylated proteins.
|Additional Information:||© 1992 by the American Society for Microbiology. Received 29 July 1991/Accepted 13 November 1991. We thank R. Birge, D. Cowburn, M. Matsuda, and M. Scott for helpful comments on the manuscript. We are extremely grateful to M. Overduin and D. Cowburn, who provided NMR spectra and many discussions on protein structure. This work was supported by Public Health Service grant CA 51462 and National Research Service award CA 08875 from the National Cancer Institute. R.A.V. is a Lucille P. Markey Scholar and was supported in part by the Lucille P. Markey Charitable Trust. NMR facilities at Rockefeller University were purchased with grants from the National Institutes of Health, the National Science Foundation, and the Keck Foundation.|
|PubMed Central ID:||PMC364250|
|Usage Policy:||No commercial reproduction, distribution, display or performance rights in this work are provided.|
|Deposited By:||Archive Administrator|
|Deposited On:||23 Dec 2008 16:30|
|Last Modified:||04 Apr 2017 22:44|
Repository Staff Only: item control page